drugset
Drugs / CAB-AXL-ADC
last change Oct 2025 re-read 3 minutes ago

CAB-AXL-ADC

also known as BA3011

targets AXL

Developed for
non-small cell lung carcinoma
Investigated by
BioAtla, Inc.

Trials 1

today NCT04681131 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04681131 Mar 2021 → Jul 2025 non-small cell lung carcinoma BioAtla, Inc. Completed No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2025-10-03 BioAtla, Inc. BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 bioatla.com ↗
2024-12-16 BioAtla, Inc. BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting bioatla.com ↗
2023-11-28 BioAtla, Inc. BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC bioatla.com ↗
2022-01-10 BioAtla, Inc. BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors bioatla.com ↗
2018-03-06 BioAtla, Inc. BioAtla Announces First Patient Treated in CAB-AXL-ADC Phase 1/2 Clinical Trial BA3011-001 bioatla.com ↗
2018-01-22 BioAtla, Inc. BioAtla Announces FDA Clearance of IND Application for CAB-AXL-ADC Therapeutic bioatla.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CAB-AXL-ADC ClinicalTrials.gov intervention name — accepted as the source's own label NCT04681131 ↗
Known as BA3011 “BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT04681131 ↗
Target AXL “AXL-targeted antibody drug conjugate” NCT04681131 ↗